Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year

BioWorld� published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025.

As the biopharma and med-tech industries continue to evolve, 2024 proved to be a landmark year. The comprehensive recap by BioWorld highlights therapeutic breakthroughs in psychiatry, oncology, women's health and infectious diseases, alongside economic highs and lows that challenged the global landscape. The series also examines regulatory changes, including U.S. court cases and international policy shifts, that could shape the future of drug pricing, reimbursement, and innovation.

Lynn Yoffee, Publisher of BioWorld, said: "The 2024 Year in Review series provides a powerful lens into the transformative events and advancements that shaped our industry this year. With our team of expert journalists and analysts, we strive to distill complex developments into actionable insights, empowering stakeholders to make informed decisions as they navigate 2025 and beyond."

Key Highlights of the BioWorld 2024 Year in Review Series:

BioWorld Year in Review: This section highlights the top mergers and acquisitions, licensing deals, financings, and first approvals of 2024. It also provides insights into key therapeutic trends such as GLP-1 receptor agonists, antibody-drug conjugates (ADCs), psychedelics, and the evolving role of precision psychiatry, alongside innovations spurred by the pandemic. Featured articles include:

BioWorld MedTech Year in Review: This section recaps key med-tech and diagnostic breakthroughs, covering cutting-edge advancements in brain mapping and pregnancy health, as well as regulatory developments expected to impact the sector in 2025. Coverage includes: 

BioWorld Science Year in Review: This section explores key research milestones, featuring global collaborations in infectious diseases, breakthroughs in curable tumors and innovations in women's health and neuroscience. Key highlights include:

The series also includes the BioWorld editorial picks for the "Best of 2024," dynamic infographics summarizing key data, and a global perspective on funding and policy changes across Europe and Asia.

To access the full BioWorld special series, visit https://www.bioworld.com/special_reports.  

Join the conversation and mention BioWorld on X and LinkedIn as well as Clarivate for Life Sciences & Healthcare on X and LinkedIn. 

About BioWorld With writers and editors stationed around the globe, BioWorld published by Clarivate, reports the breaking news - and provides key perspective on thousands of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 70 awards dating back to 1998.

About ClarivateClarivate� is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.Clarivate.com.

Media Contact:Catherine DanielDirector, External Communications, Life Sciences & Healthcarenewsroom@Clarivate.com

SOURCE Clarivate Plc

SOURCE: Clarivate Plc

COMTEX_461892899/2197/2025-01-16T03:00:00